MUVON Therapeutics AG
Our aim is to establish personalized treatments to help patients with Stress Urinary Incontinence regain control of their lives by offering them minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue.
ATLyphe AG
The novel bispecific T-cell engaging antibody has the potential to transform current hematopoietic stem cell transplantation practice into an immunologic precision-medicine approach.
Apersys AG
Our aim is to develop a perfusion technology to preserve and regenerate livers outside of the body to make more livers available to patients suffering from liver cancer or liver failure.
Nanoflex Robotics AG
Our aim is to develop a soft robotic system to simplify and shorten procedure times and reduce the risks related to accessing the brain for mechanical interventional stroke treatment.
LifeMatrix Technologies AG
Our aim is to develop a unique tissue engineering technology to grow replacement tissue in the laboratory that is compatible with any patient and that regenerates and grows with the recipient.
Voliro AG
Many tasks requiring physical contact in difficult-to-access areas, including contact-based inspection and the painting, coating, and cleaning of elevated structures, cannot be executed with currently available technology due to their design limitations.
NovaGo Therapeutics AG
Our aim is to enhance long-term axonal regeneration in the injured central nervous system and improve functional recovery.
hemotune AG
Our aim is to develop a proprietary magnetic nanoparticle technology, the HemoSystem, to allow more selective, efficient, and milder removal of disease-related compounds in patients’ blood.
PATHOS
Our aim is to remove technological difficulties from the process of art making in efforts to use robotics technologies as a new medium of human communication.